CL2017000954A1 - Moléculas de unión a antígeno biespecificas activadoras de células t - Google Patents
Moléculas de unión a antígeno biespecificas activadoras de células tInfo
- Publication number
- CL2017000954A1 CL2017000954A1 CL2017000954A CL2017000954A CL2017000954A1 CL 2017000954 A1 CL2017000954 A1 CL 2017000954A1 CL 2017000954 A CL2017000954 A CL 2017000954A CL 2017000954 A CL2017000954 A CL 2017000954A CL 2017000954 A1 CL2017000954 A1 CL 2017000954A1
- Authority
- CL
- Chile
- Prior art keywords
- molecules
- union
- bispecific
- antigen binding
- binding molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE GENERALMENTE A NUEVAS MOLÉCULAS DE UNIÓN A ANTÍGENO BIESPECÍFICAS PARA LA ACTIVACIÓN DE CÉLULAS T Y SU REDIRECCIONAMIENTO A CÉLULAS DIANA ESPECIFICAS. ADEMÁS, LA PRESENTE INVENCIÓN SE REFIERE A POLINUCLEÓTIDOS QUE CODIFICAN DICHAS MOLÉCULAS DE UNIÓN A ANTÍGENO BIESPECÍFICAS, Y A VECTORES Y CÉLULAS HOSPEDADORAS QUE COMPRENDEN DICHOS POLINUCLEÓTIDOS. LA INVENCIÓN SE REFIERE ADEMÁS A MÉTODOS PARA PRODUCIR LAS MOLÉCULAS DE UNIÓN A ANTÍGENO BIESPECÍFICAS DE LA INVENCIÓN, Y A MÉTODOS PARA USAR ESTAS MOLÉCULAS DE UNIÓN A ANTÍGENO BIESPECÍFICAS EN EL TRATAMIENTO DE ENFERMEDADES.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14194147 | 2014-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017000954A1 true CL2017000954A1 (es) | 2017-12-29 |
Family
ID=52100988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017000954A CL2017000954A1 (es) | 2014-11-20 | 2017-04-18 | Moléculas de unión a antígeno biespecificas activadoras de células t |
Country Status (33)
Country | Link |
---|---|
US (3) | US20160208019A1 (es) |
EP (1) | EP3221356B1 (es) |
JP (2) | JP7146395B2 (es) |
KR (1) | KR102648966B1 (es) |
CN (1) | CN107074955B (es) |
AR (1) | AR102732A1 (es) |
AU (1) | AU2015348595B2 (es) |
BR (1) | BR112017007086A2 (es) |
CA (1) | CA2960929A1 (es) |
CL (1) | CL2017000954A1 (es) |
CO (1) | CO2017003048A2 (es) |
CR (1) | CR20170203A (es) |
DK (1) | DK3221356T3 (es) |
EA (1) | EA201791121A1 (es) |
ES (1) | ES2829829T3 (es) |
HR (1) | HRP20201747T1 (es) |
HU (1) | HUE051715T2 (es) |
IL (1) | IL251292A0 (es) |
LT (1) | LT3221356T (es) |
MA (1) | MA40972B1 (es) |
MX (1) | MX2017006571A (es) |
MY (1) | MY184889A (es) |
PE (1) | PE20170585A1 (es) |
PH (1) | PH12017500939A1 (es) |
PL (1) | PL3221356T3 (es) |
PT (1) | PT3221356T (es) |
RS (1) | RS61010B1 (es) |
SG (1) | SG11201702976TA (es) |
SI (1) | SI3221356T1 (es) |
TW (2) | TWI756164B (es) |
UA (1) | UA122676C2 (es) |
WO (1) | WO2016079076A1 (es) |
ZA (1) | ZA201701843B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11672858B2 (en) | 2018-12-21 | 2023-06-13 | Hoffmann-La Roche Inc. | Bispecific antibody molecules binding to CD3 and TYRP-1 |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
US10087250B2 (en) | 2012-10-08 | 2018-10-02 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
RS59992B1 (sr) | 2013-02-26 | 2020-04-30 | Roche Glycart Ag | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije specifični za cd3 i cea |
RU2015140915A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
KR20160044060A (ko) * | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
MY179611A (en) | 2014-08-04 | 2020-11-11 | Hoffmann La Roche | Bispecific t cell activating antigen binding molecules |
EP4141032A1 (en) | 2014-11-20 | 2023-03-01 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CA2990755A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffman-La Roche Ag | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
WO2017097723A2 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Treatment method |
US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
DK3433280T3 (da) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-aktiverede T-celle-bispecifikke molekyler |
JP7022123B2 (ja) * | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3に対する二重特異性抗体 |
US10654929B2 (en) | 2016-11-02 | 2020-05-19 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
WO2018108759A1 (en) * | 2016-12-13 | 2018-06-21 | F. Hoffmann-La Roche Ag | Method to determine the presence of a target antigen in a tumor sample |
EP3554542A1 (en) | 2016-12-19 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
JP2020527332A (ja) * | 2017-06-12 | 2020-09-10 | ブルーフィン バイオメディシン, インコーポレイテッド | 抗−il1rap抗体および抗体薬物コンジュゲート |
HRP20211744T1 (hr) * | 2017-07-14 | 2022-02-04 | Immatics Biotechnologies Gmbh | Poboljšana molekula polipeptida dvostruke specifičnosti |
EP3704155A2 (en) * | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Combination therapy with targeted ox40 agonists |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
US20200339685A1 (en) * | 2017-12-27 | 2020-10-29 | Teneobio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
AU2019218959A1 (en) | 2018-02-08 | 2020-09-03 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
BR112020016469A2 (pt) * | 2018-03-13 | 2020-12-15 | Phanes Therapeutics, Inc. | Anticorpos do receptor anti-folato 1 e seus usos |
AU2019235652A1 (en) * | 2018-03-13 | 2020-10-01 | Immunewalk Therapeutics, Inc. | Bispecific antibodies to MOSPD2 and T cell- or NK cell-specific molecules |
CN117866095A (zh) * | 2018-07-09 | 2024-04-12 | 普众发现医药科技(上海)有限公司 | 叶酸受体α特异性抗体 |
EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG-BINDING MOLECULES |
JP6935383B2 (ja) * | 2018-09-27 | 2021-09-15 | 公益財団法人実験動物中央研究所 | 免疫不全マウス |
WO2020067199A1 (ja) * | 2018-09-27 | 2020-04-02 | 公益財団法人実験動物中央研究所 | 免疫不全マウス |
BR112021012101A2 (pt) | 2018-12-21 | 2021-09-08 | F. Hoffmann-La Roche Ag | Moléculas de ligação ao antígeno agonístico cd28 biespecífico, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula, composição farmacêutica, uso da molécula e método de inibição do crescimento de células tumorais |
MX2021014433A (es) * | 2019-06-05 | 2022-03-11 | Chugai Pharmaceutical Co Ltd | Molecula de union a sitio de escision de anticuerpo. |
BR112021025401A2 (pt) * | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo trivalente, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante, composição e método para produzir uma célula de mamífero recombinante |
KR20220024636A (ko) | 2019-06-19 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 다가, 다중특이성 항체 발현 세포의 생성 방법 |
CN114531878A (zh) | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子 |
CA3146566A1 (en) * | 2019-07-11 | 2021-01-14 | Memorial Sloan Kettering Cancer Center | Dll3-targeting antibodies and uses thereof |
CN111018969A (zh) * | 2019-12-27 | 2020-04-17 | 上海药明生物技术有限公司 | 采用轻链select联合层析色谱纯化双特异性抗体的方法 |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
PE20230835A1 (es) * | 2020-06-19 | 2023-05-19 | Hoffmann La Roche | Anticuerpos que se unen a cd3 |
WO2021255146A1 (en) * | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
AR122656A1 (es) | 2020-06-19 | 2022-09-28 | Hoffmann La Roche | Anticuerpos que se unen a cd3 / folr1 |
MX2022016069A (es) * | 2020-06-19 | 2023-02-02 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19. |
JP2023544769A (ja) * | 2020-10-07 | 2023-10-25 | アムジエン・インコーポレーテツド | 多重特異性抗体の構築のためのビルディングブロックの合理的選択 |
TW202233684A (zh) * | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
CA3237018A1 (en) * | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5612663B2 (ja) * | 2009-04-07 | 2014-10-22 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗ErbB−1/抗c−Met抗体 |
UA116192C2 (uk) * | 2011-08-23 | 2018-02-26 | Рош Глікарт Аг | Активуюча т-клітини біоспецифічна антигензв'язуюча молекула |
CA2883222C (en) * | 2012-08-31 | 2021-12-14 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
CN104884617B (zh) * | 2012-12-07 | 2019-02-19 | 协和发酵麒麟株式会社 | 抗folr1抗体 |
JP6233933B2 (ja) * | 2012-12-25 | 2017-11-22 | 国立大学法人 鹿児島大学 | 葉酸リセプターα及びβを認識する抗体 |
RU2015140915A (ru) * | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
US11634502B2 (en) * | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
KR20150130349A (ko) * | 2013-03-15 | 2015-11-23 | 메르크 파텐트 게엠베하 | 4가 이중특이적 항체 |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
EP3049440B1 (en) * | 2013-09-25 | 2020-03-25 | Amgen Inc. | V-c-fc-v-c antibody |
-
2015
- 2015-11-17 MY MYPI2017701790A patent/MY184889A/en unknown
- 2015-11-17 LT LTEP15797970.9T patent/LT3221356T/lt unknown
- 2015-11-17 KR KR1020177013403A patent/KR102648966B1/ko active IP Right Grant
- 2015-11-17 EP EP15797970.9A patent/EP3221356B1/en active Active
- 2015-11-17 MA MA40972A patent/MA40972B1/fr unknown
- 2015-11-17 MX MX2017006571A patent/MX2017006571A/es unknown
- 2015-11-17 RS RS20201312A patent/RS61010B1/sr unknown
- 2015-11-17 AU AU2015348595A patent/AU2015348595B2/en active Active
- 2015-11-17 CR CR20170203A patent/CR20170203A/es unknown
- 2015-11-17 BR BR112017007086A patent/BR112017007086A2/pt active Search and Examination
- 2015-11-17 CA CA2960929A patent/CA2960929A1/en active Pending
- 2015-11-17 UA UAA201706105A patent/UA122676C2/uk unknown
- 2015-11-17 ES ES15797970T patent/ES2829829T3/es active Active
- 2015-11-17 PL PL15797970T patent/PL3221356T3/pl unknown
- 2015-11-17 SG SG11201702976TA patent/SG11201702976TA/en unknown
- 2015-11-17 DK DK15797970.9T patent/DK3221356T3/da active
- 2015-11-17 PE PE2017000543A patent/PE20170585A1/es unknown
- 2015-11-17 PT PT157979709T patent/PT3221356T/pt unknown
- 2015-11-17 EA EA201791121A patent/EA201791121A1/ru unknown
- 2015-11-17 HU HUE15797970A patent/HUE051715T2/hu unknown
- 2015-11-17 SI SI201531404T patent/SI3221356T1/sl unknown
- 2015-11-17 CN CN201580059475.0A patent/CN107074955B/zh active Active
- 2015-11-17 WO PCT/EP2015/076739 patent/WO2016079076A1/en active Application Filing
- 2015-11-17 JP JP2017527224A patent/JP7146395B2/ja active Active
- 2015-11-19 TW TW104138283D patent/TWI756164B/zh active
- 2015-11-19 TW TW104138283A patent/TW201632556A/zh unknown
- 2015-11-20 AR ARP150103792A patent/AR102732A1/es unknown
- 2015-11-20 US US14/947,657 patent/US20160208019A1/en not_active Abandoned
-
2017
- 2017-03-15 ZA ZA2017/01843A patent/ZA201701843B/en unknown
- 2017-03-20 IL IL251292A patent/IL251292A0/en active IP Right Grant
- 2017-03-29 CO CONC2017/0003048A patent/CO2017003048A2/es unknown
- 2017-04-18 CL CL2017000954A patent/CL2017000954A1/es unknown
- 2017-05-19 PH PH12017500939A patent/PH12017500939A1/en unknown
-
2018
- 2018-06-22 US US16/016,209 patent/US20190031784A1/en not_active Abandoned
-
2020
- 2020-10-29 HR HRP20201747TT patent/HRP20201747T1/hr unknown
- 2020-12-02 JP JP2020200433A patent/JP2021058189A/ja active Pending
-
2022
- 2022-01-20 US US17/580,248 patent/US20220220224A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11672858B2 (en) | 2018-12-21 | 2023-06-13 | Hoffmann-La Roche Inc. | Bispecific antibody molecules binding to CD3 and TYRP-1 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CO2017013710A2 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t. | |
AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CL2018000431A1 (es) | Anticuerpos anti-bcma, moléculas de unión de antígeno específicas que vinculan bcma y cd3, y sus usos relacionados. | |
AR094896A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
CR20150048A (es) | Anticuerpos e inmunoconjugados anti-cd22 | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
CO7151529A2 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
UY35399A (es) | Conjugados de fármacos con anticuerpos | |
ECSP14013220A (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
ECSP14005975A (es) | Anticuerpos anti-PHF-tau y sus usos | |
CO2017003005A2 (es) | Anticuerpos anti-mfi2 | |
BR112016018313A2 (pt) | moléculas de ligação multiespecíficas iga | |
BR112016017597A2 (pt) | Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo | |
AR113343A1 (es) | ANTICUERPO MONOCLONAL ANTI-IL-5Ra | |
AR119972A2 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CR20150259A (es) | Anticuerpos egfr/c-met biespecíficos |